Litcius/Paper detail

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy

André Scheen

2024Drugs40 citationsDOI

Topics & Concepts

MedicineType 2 diabetesPharmacotherapyDiabetes mellitusPharmacologyGlucagon-like peptide 1 receptorReceptorInternal medicineEndocrinologyAgonistBioinformaticsBiologyDiabetes Treatment and ManagementPharmacology and Obesity TreatmentDiet and metabolism studies
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy | Litcius